These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 38175307)

  • 1. PD-L1-positive circulating endothelial progenitor cells associated with immune response to PD-1 blockade in patients with head and neck squamous cell carcinoma.
    Su NW; Dai SH; Hsu K; Chang KM; Ko CC; Kao CW; Chang YF; Chen CG
    Cancer Immunol Immunother; 2024 Jan; 73(1):3. PubMed ID: 38175307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
    Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
    Front Immunol; 2021; 12():645170. PubMed ID: 33897693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of downregulating FEN1 and PD-1 blockade enhances antitumor activity of CD8+ T cells against HNSCC cells in vitro.
    Wang X; Xu S; Fu T; Wu Y; Sun W
    J Oral Pathol Med; 2023 Oct; 52(9):834-842. PubMed ID: 37728572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy.
    Chen Y; Ding X; Bai X; Zhou Z; Liu Y; Zhang X; Yu J; Hu M
    Int Immunopharmacol; 2023 Jul; 120():110329. PubMed ID: 37207445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant PD-1/PD-L1 axis blockade for patients with head and neck squamous cell carcinoma.
    Huang S; Xiong C; Tan K
    Am J Otolaryngol; 2023; 44(6):103985. PubMed ID: 37442083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.
    Ngamphaiboon N; Chureemas T; Siripoon T; Arsa L; Trachu N; Jiarpinitnun C; Pattaranutaporn P; Sirachainan E; Larbcharoensub N
    Med Oncol; 2019 Jan; 36(2):21. PubMed ID: 30666437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma.
    Gavrielatou N; Fortis E; Spathis A; Anastasiou M; Economopoulou P; Foukas GRP; Lelegiannis IM; Rusakiewicz S; Vathiotis I; Aung TN; Tissot S; Kastrinou A; Kotsantis I; Vagia EM; Panayiotides I; Rimm DL; Coukos G; Homicsko K; Foukas P; Psyrri A
    Ann Oncol; 2024 Apr; 35(4):340-350. PubMed ID: 38159908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of Intra-tumoral and Peripheral PD-1/PD-L1 Immunity in Head and Neck Cancer.
    Idel C; Ribbat-Idel J; VON Bernuth A; Fleckner J; Rades D; Kirfel J; Sailer V; Plötze-Martin K; Bruchhage KL; Pries R
    Anticancer Res; 2023 Dec; 43(12):5349-5358. PubMed ID: 38030173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
    Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
    Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
    Front Immunol; 2020; 11():1721. PubMed ID: 33072064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
    Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
    J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
    Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
    J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brusatol improves the efficacy of an anti-mouse-PD-1 antibody via inhibiting programmed cell death 1 ligand 1 expression in a murine head and neck squamous cell carcinoma model.
    Wu Y; Zhang G; Yin P; Wen J; Su Y; Zhang X
    Arch Oral Biol; 2024 Oct; 166():106043. PubMed ID: 38968906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
    Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
    Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.
    Strati A; Koutsodontis G; Papaxoinis G; Angelidis I; Zavridou M; Economopoulou P; Kotsantis I; Avgeris M; Mazel M; Perisanidis C; Sasaki C; Alix-Panabières C; Lianidou E; Psyrri A
    Ann Oncol; 2017 Aug; 28(8):1923-1933. PubMed ID: 28838214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mild hyperthermia upregulates PD-L1 in the tumor microenvironment and enhances antitumor efficacy of PD-L1 blockade in murine squamous cell carcinoma.
    Ohta Y; Ichimura N; Yamaguchi S; Ohara G; Yamamoto N; Itoh Y; Yamada K; Nakamura S; Hibi H
    Nagoya J Med Sci; 2024 Aug; 86(3):497-506. PubMed ID: 39355357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitor monotherapy is sufficient to promote microenvironmental normalization via the type I interferon pathway in PD-L1-expressing head and neck cancer.
    Jang JY; Lee BS; Huang M; Seo C; Choi JH; Shin YS; Woo HG; Kim CH
    Mol Oncol; 2024 Aug; 18(8):1923-1939. PubMed ID: 38511232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials.
    Zhu P; Wang Y; Zhang W; Liu X
    Medicine (Baltimore); 2021 Jan; 100(4):e24339. PubMed ID: 33530227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma.
    Evrard D; Hourseau M; Couvelard A; Paradis V; Gauthier H; Raymond E; Halimi C; Barry B; Faivre S
    Oncoimmunology; 2020 Nov; 9(1):1844403. PubMed ID: 33299655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.